Acquired and inherited lipodystrophies.

Lipodystrophies, heterogeneous acquired or inherited disorders characterized by the selective loss of adipose tissue, predispose affected patients to insulin resistance and its attendant complications. This review focuses on the clinical features, underlying pathogenetic mechanisms, and management of various types of acquired and inherited lipodystrophies.

[1]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[2]  A. Garg,et al.  Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy: Report of 35 Cases and Review of the Literature , 2004, Medicine.

[3]  R. Peshock,et al.  The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy , 2004, Skeletal Radiology.

[4]  A. Garg,et al.  Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. , 2003, The Journal of clinical endocrinology and metabolism.

[5]  S. O’Rahilly,et al.  Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  A. K. Agarwal,et al.  Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. , 2003, Human molecular genetics.

[7]  A. K. Agarwal,et al.  Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. , 2003, The Journal of clinical endocrinology and metabolism.

[8]  M. Lathrop,et al.  Prevalence of mutations in AGPAT2 among human lipodystrophies. , 2003, Diabetes.

[9]  A. Chait,et al.  Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. , 2003, Diabetes care.

[10]  A. K. Agarwal,et al.  Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. , 2003, Diabetes care.

[11]  Jimmy D Bell,et al.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.

[12]  A. Garg,et al.  Clinical Features and Metabolic Derangements in Acquired Generalized Lipodystrophy: Case Reports and Review of the Literature , 2003, Medicine.

[13]  A. Cohen,et al.  A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  A. Garg,et al.  Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. , 2003, Diabetes care.

[15]  A. Garg,et al.  Post‐mortem findings in familial partial lipodystrophy, Dunnigan variety , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[16]  R. Hegele,et al.  PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. , 2002, Diabetes.

[17]  A. Häkkinen,et al.  Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy , 2002, AIDS.

[18]  A. Garg,et al.  Lipodystrophy in Human Immunodeficiency Virus-Infected Patients , 2002 .

[19]  J. Carruthers,et al.  HIV‐Associated Facial Lipoatrophy , 2002, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[20]  S. O’Rahilly,et al.  Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy , 2002, Journal of medical genetics.

[21]  P. Reiss,et al.  Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. , 2002, Neurology.

[22]  G. Scarano,et al.  Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. , 2002, American journal of human genetics.

[23]  C. Stewart,et al.  Life at the edge: the nuclear envelope and human disease , 2002, Nature Reviews Molecular Cell Biology.

[24]  K. Petersen,et al.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.

[25]  Y. Matsuzawa,et al.  Serum adiponectin and leptin levels in patients with lipodystrophies , 2002 .

[26]  A. Bowcock,et al.  Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A/C gene. , 2002, The American journal of medicine.

[27]  Molecular analysis of Berardinelli-Seip congenital lipodystrophy in Oman: evidence for multiple loci. , 2002, Diabetes.

[28]  R. Trembath,et al.  A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. , 2002, Human molecular genetics.

[29]  W. Rozenbaum,et al.  Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance , 2002, The Lancet.

[30]  C. Fichtenbaum,et al.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 , 2002, AIDS.

[31]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[32]  M. Schambelan,et al.  Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. , 2002, The Journal of clinical endocrinology and metabolism.

[33]  R. Greenblatt,et al.  Effectiveness of highly active antiretroviral therapy among HIV-1 infected women , 2002, Journal of epidemiology and community health.

[34]  A. Garg,et al.  Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  C. Lelliott,et al.  Lamin expression in human adipose cells in relation to anatomical site and differentiation state. , 2002, The Journal of clinical endocrinology and metabolism.

[36]  A. Garg,et al.  A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .

[37]  Simeon I. Taylor,et al.  Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. , 2002, The Journal of clinical endocrinology and metabolism.

[38]  A. Bowcock,et al.  AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.

[39]  C. Vigouroux,et al.  Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. , 2001, Journal of cell science.

[40]  Jie Chen,et al.  Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.

[41]  S. Mallal,et al.  HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study , 2001, AIDS.

[42]  Marco Zoli,et al.  Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.

[43]  J. Papp,et al.  Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13 , 2001, Nature Genetics.

[44]  D. Leung.  The structure and functions of human lysophosphatidic acid acyltransferases. , 2001, Frontiers in bioscience : a journal and virtual library.

[45]  R. Gilroy,et al.  LIPOATROPHIC DIABETES AND END-STAGE LIVER DISEASE SECONDARY TO NONALCOHOLIC STEATOHEPATITIS WITH RECURRENCE AFTER LIVER TRANSPLANTATION , 2001, Transplantation.

[46]  R. Petty,et al.  Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities. , 2001, The Journal of rheumatology.

[47]  A. Bowcock,et al.  Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. , 2001, The Journal of clinical endocrinology and metabolism.

[48]  C. Flexner,et al.  Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* , 2000, The Journal of Biological Chemistry.

[49]  R. Trembath,et al.  Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. , 2000, Diabetes.

[50]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.

[51]  P. Hruz,et al.  The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.

[52]  P. Puigserver,et al.  Transcriptional regulation of adipogenesis. , 2000, Genes & development.

[53]  A. Garg.  Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). , 2000 .

[54]  M. Lovett,et al.  Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. , 2000, American journal of human genetics.

[55]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[56]  S. Gregory,et al.  LMNA, encoding lamin A/C, is mutated in partial lipodystrophy , 2000, Nature Genetics.

[57]  E. Pivnick,et al.  Neonatal progeroid (Wiedemann-Rautenstrauch) syndrome: report of five new cases and review. , 2000, American journal of medical genetics.

[58]  R. Hegele,et al.  Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. , 2000, Human molecular genetics.

[59]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[60]  X. Matías-Guiu,et al.  Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. , 1999, AIDS.

[61]  A. Bowcock,et al.  A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. , 1999, The Journal of clinical endocrinology and metabolism.

[62]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[63]  A. J. Mcadams,et al.  The alternative pathway C3 convertase and glomerular deposits , 1999, Pediatric Nephrology.

[64]  F. Schick,et al.  Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.

[65]  R. Peshock,et al.  Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). , 1999, The Journal of clinical endocrinology and metabolism.

[66]  M. Schambelan,et al.  Body shape changes in HIV-infected patients. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[67]  M. Olive,et al.  Life without white fat: a transgenic mouse. , 1998, Genes & development.

[68]  R. Hammer,et al.  Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. , 1998, Genes & development.

[69]  D. Jakubowicz,et al.  Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. , 1998, The New England journal of medicine.

[70]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[71]  A. Bowcock,et al.  Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21–22 , 1998, Nature Genetics.

[72]  J. Currier,et al.  Protease inhibitor-associated hyperglycaemia , 1997, The Lancet.

[73]  A. Kumar,et al.  Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. , 1997, DNA and cell biology.

[74]  O. Trygstad,et al.  Generalized lipodystrophy, congenital and acquired (lipoatrophy) , 1996, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[75]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[76]  M. Chandalia,et al.  Severe Islet Amyloidosis in Congenital Generalized Lipodystrophy , 1996, Diabetes Care.

[77]  M. Chandalia,et al.  Postmortem findings in congenital generalized lipodystrophy. , 1995, The Journal of clinical endocrinology and metabolism.

[78]  P. Mathieson,et al.  Are nephritic factors nephritogenic? , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[79]  H. Worman,et al.  Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. , 1993, The Journal of biological chemistry.

[80]  P. Lachmann,et al.  Complement-mediated adipocyte lysis by nephritic factor sera , 1993, The Journal of experimental medicine.

[81]  S. Grundy,et al.  Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. , 1992, The Journal of clinical endocrinology and metabolism.

[82]  A. Torrelo,et al.  Partial lipodystrophy and dermatomyositis. , 1991, Archives of dermatology.

[83]  D. Cutler,et al.  Insulin-resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized form of partial lipodystrophy. , 1991, The Journal of clinical endocrinology and metabolism.

[84]  J. Billings,et al.  Lipoatrophic panniculitis: a possible autoimmune inflammatory disease of fat. Report of three cases. , 1987, Archives of dermatology.

[85]  G. Blobel,et al.  cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[86]  J. Köbberling,et al.  Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. , 1986, Journal of medical genetics.

[87]  Jasin He.  Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia. , 1979 .

[88]  P. Duffus,et al.  Identification of nephritic factor as an immunoglobulin. , 1978, Clinical and experimental immunology.

[89]  Sensenbrenner Ja,et al.  A low birthweight syndrome, ? Rieger syndrome. , 1975 .

[90]  M. Dunnigan,et al.  Familial lipoatrophic diabetes with dominant transmission. A new syndrome. , 1974, The Quarterly journal of medicine.

[91]  S. Imamura,et al.  Lipodystrophia centrifugalis abdominalis infantilis. , 1971, Archives of dermatology.

[92]  V. McKusick,et al.  New syndrome manifested by mandibular hypoplasia, acroosteolysis, stiff joints and cutaneous atrophy (mandibuloacral dysplasia) in two unrelated boys. , 1971, Birth defects original article series.

[93]  M. Seip.  Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? , 1959, Acta paediatrica.

[94]  W. Berardinelli.  An undiagnosed endocrinometabolic syndrome: report of 2 cases. , 1954, The Journal of clinical endocrinology and metabolism.

[95]  A. Simons.  Eine seltene trophoneurose („Iipodystrophia progressiva“) , 1911 .

[96]  S. W. Mitchell.  SINGULAR CASE OF ABSENCE OF ADIPOSE MATTER IN THE UPPER HALF OF THE BODY , 1885 .